{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:06:54Z","timestamp":1783012014721,"version":"3.54.6"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":1893,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Terminal complement pathway inhibition at the level of C5 alleviates symptoms of several diseases associated with complement overactivation. However, C5 blockade is associated with an increased risk of invasive meningococcal disease despite immunization. Targeting specific complement pathways proximal to C5 provides the theoretical advantage of leaving the other pathways (including the terminal pathway) intact for immune surveillance. We aimed to address the risk of Neisseria meningitidis and Streptococcus pneumoniae infections when inhibiting the classical pathway (CP) using a specific C1s inhibitor (TNT005). Addition of TNT005 to 20% normal human serum that contained anti-meningococcal capsular Ab decreased C4 deposition 8-fold and abrogated killing of N. meningitidis, despite leaving C3 deposition intact. TNT005 impaired killing of N. meningitidis in 78% nonimmune human plasma and 78% whole blood but permitted killing in both when specific anti-capsular Ab was added. Simultaneously inhibiting both the CP and alternative pathway (AP) blocked killing of Ab-coated N. meningitidis in whole blood. Blocking the AP alone abrogated C3 deposition, whereas TNT005 only partially inhibited (\u223c40% decrease) C3 deposition on S. pneumoniae coated with anti-capsular Ab. Blocking either the CP or AP alone did not impair killing of pneumococci in whole blood containing specific Ab (&amp;lt;10% survival at 3 h); however, blocking both pathways resulted in \u223c35% bacterial survival. These data suggest that killing of N. meningitidis or S. pneumoniae in whole blood containing specific anti-capsular Abs is unimpeded by TNT005. Meningococcal and pneumococcal capsular conjugate vaccines may mitigate risk of these infections in patients receiving C1s inhibitors.<\/jats:p>","DOI":"10.4049\/immunohorizons.1900031","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T21:15:15Z","timestamp":1572988515000},"page":"519-530","source":"Crossref","is-referenced-by-count":12,"title":["Effect of a C1s Inhibitor on the Efficacy of Anti-Capsular Antibodies against <i>Neisseria meningitidis<\/i> and <i>Streptococcus pneumoniae<\/i>"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-9083","authenticated-orcid":false,"given":"Lisa A","family":"Lewis","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School , Worcester, MA 01605"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7901-2730","authenticated-orcid":false,"given":"Sandip","family":"Panicker","sequence":"additional","affiliation":[{"name":"Bioverativ, a Sanofi company , Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane B","family":"DeOliveira","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School , Worcester, MA 01605"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham C","family":"Parry","sequence":"additional","affiliation":[{"name":"Bioverativ, a Sanofi company , Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Ram","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School , Worcester, MA 01605"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2025010608420221300_r1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/CMR.4.3.359","article-title":"Infectious diseases associated with complement deficiencies","volume":"4","author":"Figueroa","year":"1991","journal-title":"Clin. Microbiol. Rev."},{"key":"2025010608420221300_r2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat. Immunol."},{"key":"2025010608420221300_r3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nri.2017.97","article-title":"Complement in cancer: untangling an intricate relationship","volume":"18","author":"Reis","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"2025010608420221300_r4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"2025010608420221300_r5","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Complement. Second of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2025010608420221300_r6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"2025010608420221300_r7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neurobiolaging.2016.12.017","article-title":"A review of human diseases caused or exacerbated by aberrant complement activation","volume":"52","author":"McGeer","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"2025010608420221300_r8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.ai.2017.06.004","article-title":"Complement system in neural synapse elimination in development and disease","volume":"135","author":"Presumey","year":"2017","journal-title":"Adv. Immunol."},{"key":"2025010608420221300_r9","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J. Immunol."},{"key":"2025010608420221300_r10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J. Immunol."},{"key":"2025010608420221300_r11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00281-017-0663-8","article-title":"Diseases of complement dysregulation-an overview","volume":"40","author":"Wong","year":"2018","journal-title":"Semin. Immunopathol."},{"key":"2025010608420221300_r12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev."},{"key":"2025010608420221300_r13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"key":"2025010608420221300_r14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.hoc.2015.01.002","article-title":"Cold agglutinin-mediated autoimmune hemolytic anemia","volume":"29","author":"Berentsen","year":"2015","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"2025010608420221300_r15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3816\/CLM.2005.n.019","article-title":"Cold agglutinin disease and cryoglobulinemia","volume":"5","author":"Gertz","year":"2005","journal-title":"Clin. Lymphoma"},{"key":"2025010608420221300_r16","first-page":"211","article-title":"Role of complement in the pathophysiology of hematologic diseases","volume":"10","author":"Atkinson","year":"1977","journal-title":"Prog. Hematol."},{"key":"2025010608420221300_r17","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"2025010608420221300_r18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood.V130.Suppl_1.703.703","article-title":"Long term efficacy, safety and PK\/PD profile of the anti-C1s antibody (BIVV009) in primary cold agglutinin disease patients","volume":"130","author":"Jaeger","year":"2017","journal-title":"Blood"},{"key":"2025010608420221300_r19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"Jager","year":"2019","journal-title":"Blood"},{"key":"2025010608420221300_r20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02918259","article-title":"Complement deficiency states and meningococcal disease","volume":"12","author":"Figueroa","year":"1993","journal-title":"Immunol. Res."},{"key":"2025010608420221300_r21","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"2025010608420221300_r22","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. [Published erratum appears in 2014 Clin. Infect. Dis. 59: 144.]","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"2025010608420221300_r23","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","article-title":"Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy","volume":"26","author":"Bouts","year":"2011","journal-title":"Pediatr. Nephrol."},{"key":"2025010608420221300_r24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"2025010608420221300_r25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am. J. Transplant."},{"key":"2025010608420221300_r26","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1126\/science.1061217","article-title":"Complete genome sequence of a virulent isolate of Streptococcus pneumoniae","volume":"293","author":"Tettelin","year":"2001","journal-title":"Science"},{"key":"2025010608420221300_r27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00006454-200004000-00012","article-title":"Meningococcal disease in Dallas County, Texas: results of a six-year population-based study","volume":"19","author":"Pastor","year":"2000","journal-title":"Pediatr. Infect. Dis. J."},{"key":"2025010608420221300_r28","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.4049\/jimmunol.1003623","article-title":"Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip\/H.8 and Laz lipoproteins","volume":"186","author":"Ray","year":"2011","journal-title":"J. Immunol."},{"key":"2025010608420221300_r29","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1074\/jbc.M110.184838","article-title":"Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement","volume":"286","author":"Ram","year":"2011","journal-title":"J. Biol. Chem."},{"key":"2025010608420221300_r30","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.4049\/jimmunol.1102746","article-title":"Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein","volume":"188","author":"Gulati","year":"2012","journal-title":"J. Immunol."},{"key":"2025010608420221300_r31","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.4049\/jimmunol.1103748","article-title":"The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci","volume":"188","author":"Lewis","year":"2012","journal-title":"J. Immunol."},{"key":"2025010608420221300_r32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.1303177","article-title":"Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides","volume":"193","author":"Agarwal","year":"2014","journal-title":"J. Immunol."},{"key":"2025010608420221300_r33","doi-asserted-by":"crossref","first-page":"e1001027","DOI":"10.1371\/journal.ppat.1001027","article-title":"The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement","volume":"6","author":"Lewis","year":"2010","journal-title":"PLoS Pathog."},{"key":"2025010608420221300_r34","doi-asserted-by":"crossref","first-page":"e00339-13","DOI":"10.1128\/mBio.00339-13","article-title":"Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis","volume":"4","author":"Lewis","year":"2013","journal-title":"MBio"},{"key":"2025010608420221300_r35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"2025010608420221300_r36","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J. Exp. Med."},{"key":"2025010608420221300_r37","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","article-title":"Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease","volume":"27","author":"Granoff","year":"2009","journal-title":"Vaccine"},{"key":"2025010608420221300_r38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1203\/00006450-199005000-00020","article-title":"Deficiencies in opsonic defense to pneumococci in the human newborn despite adequate levels of complement and specific IgG antibodies","volume":"27","author":"Geelen","year":"1990","journal-title":"Pediatr. Res."},{"key":"2025010608420221300_r39","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1084\/jem.129.6.1275","article-title":"The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors","volume":"129","author":"Johnston","year":"1969","journal-title":"J. Exp. Med."},{"key":"2025010608420221300_r40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/clinids\/3.2.289","article-title":"The role of complement in the host\u2019s defense against Streptococcus pneumoniae","volume":"3","author":"Winkelstein","year":"1981","journal-title":"Rev. Infect. Dis."},{"key":"2025010608420221300_r41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"2025010608420221300_r42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"2025010608420221300_r43","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s40265-013-0147-7","article-title":"Eculizumab: a review of its use in atypical haemolytic uraemic syndrome","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"2025010608420221300_r44","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/JCM.42.7.2898-2901.2004","article-title":"Bacteremia in an immunocompromised patient caused by a commensal Neisseria meningitidis strain harboring the capsule null locus (cnl)","volume":"42","author":"Vogel","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"2025010608420221300_r45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1086\/512084","article-title":"Three cases of invasive meningococcal disease caused by a capsule null locus strain circulating among healthy carriers in Burkina Faso","volume":"195","author":"Findlow","year":"2007","journal-title":"J. Infect. Dis."},{"key":"2025010608420221300_r46","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1086\/427875","article-title":"Rapid and fatal meningococcal disease due to a strain of Neisseria meningitidis containing the capsule null locus","volume":"40","author":"Hoang","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"2025010608420221300_r47","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12866-017-0942-5","article-title":"Molecular characterization of invasive capsule null Neisseria meningitidis in South Africa","volume":"17","author":"Ganesh","year":"2017","journal-title":"BMC Microbiol."},{"key":"2025010608420221300_r48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/cid\/ciy958","article-title":"Disseminated gonococcal infections in patients receiving eculizumab: a case series","volume":"69","author":"Crew","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"2025010608420221300_r49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jinf.2018.10.015","article-title":"Unusual Neisseria species as a cause of infection in patients taking eculizumab","volume":"78","author":"Crew","year":"2019","journal-title":"J. Infect."},{"key":"2025010608420221300_r50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.126.1.11","article-title":"The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway","volume":"126","author":"Schenkein","year":"1981","journal-title":"J. Immunol."},{"key":"2025010608420221300_r51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4049\/jimmunol.126.1.7","article-title":"The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan","volume":"126","author":"Schenkein","year":"1981","journal-title":"J. Immunol."},{"key":"2025010608420221300_r52","first-page":"123","article-title":"Inherited deficiencies of the terminal components of human complement","volume":"3","author":"W\u00fcrzner","year":"1992","journal-title":"Immunodefic. Rev."},{"key":"2025010608420221300_r53","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/eji.200636812","article-title":"Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited","volume":"37","author":"Rameix-Welti","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"2025010608420221300_r54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1172\/JCI200112023","article-title":"A family with complement factor D deficiency","volume":"108","author":"Biesma","year":"2001","journal-title":"J. Clin. Invest."},{"key":"2025010608420221300_r55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clim.2012.06.008","article-title":"Vaccination against encapsulated bacteria in hereditary C2 deficiency results in antibody response and opsonization due to antibody-dependent complement activation","volume":"144","author":"J\u00f6nsson","year":"2012","journal-title":"Clin. Immunol."},{"key":"2025010608420221300_r56","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.4049\/jimmunol.163.6.3549","article-title":"IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model","volume":"163","author":"Wagner","year":"1999","journal-title":"J. Immunol."},{"key":"2025010608420221300_r57","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.4049\/jimmunol.143.7.2256","article-title":"Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement","volume":"143","author":"Knutzen Steuer","year":"1989","journal-title":"J. Immunol."},{"key":"2025010608420221300_r58","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.4049\/jimmunol.111.6.1668","article-title":"Hemolysis of sheep erythrocytes in guinea pig serum deficient in the fourth component of complement. I. Antibody and serum requirements","volume":"111","author":"May","year":"1973","journal-title":"J. Immunol."},{"key":"2025010608420221300_r59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1084\/jem.151.5.1275","article-title":"The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus","volume":"151","author":"Edwards","year":"1980","journal-title":"J. Exp. Med."},{"key":"2025010608420221300_r60","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1128\/iai.44.2.452-458.1984","article-title":"Antibody-dependent alternative pathway killing of Haemophilus influenzae type b","volume":"44","author":"Steele","year":"1984","journal-title":"Infect. Immun."},{"key":"2025010608420221300_r61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1023\/A:1006638631581","article-title":"Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG","volume":"20","author":"Selander","year":"2000","journal-title":"J. Clin. Immunol."},{"key":"2025010608420221300_r62","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4049\/jimmunol.106.1.282","article-title":"Two complement interaction sites in guinea pig immunoglobulins","volume":"106","author":"Sandberg","year":"1971","journal-title":"J. Immunol."},{"key":"2025010608420221300_r63","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.104.2.329","article-title":"The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins","volume":"104","author":"Sandberg","year":"1970","journal-title":"J. Immunol."},{"key":"2025010608420221300_r64","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF02116280","article-title":"The role of antibody in the activation of the alternative complement pathway","volume":"6","author":"Ratnoff","year":"1983","journal-title":"Springer Semin. Immunopathol."},{"key":"2025010608420221300_r65","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj1950471","article-title":"The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum","volume":"195","author":"Gadd","year":"1981","journal-title":"Biochem. J."},{"key":"2025010608420221300_r66","doi-asserted-by":"crossref","first-page":"28997","DOI":"10.1016\/S0021-9258(19)62004-1","article-title":"Covalent attachment of human complement C3 to IgG. Identification of the amino acid residue involved in ester linkage formation","volume":"269","author":"Sahu","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2025010608420221300_r67","doi-asserted-by":"crossref","first-page":"18520","DOI":"10.1016\/S0021-9258(18)55092-4","article-title":"Localization of the human complement component C3 binding site on the IgG heavy chain","volume":"266","author":"Shohet","year":"1991","journal-title":"J. Biol. Chem."},{"key":"2025010608420221300_r68","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/S0021-9258(18)53400-1","article-title":"Identification of a major binding site for complement C3 on the IgG1 heavy chain","volume":"268","author":"Shohet","year":"1993","journal-title":"J. Biol. Chem."},{"key":"2025010608420221300_r69","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/bj3490217","article-title":"Interaction of C3b(2)\u2013IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification","volume":"349","author":"Jelezarova","year":"2000","journal-title":"Biochem. J."},{"key":"2025010608420221300_r70","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.108.832972","article-title":"Complement-dependent neutrophil recruitment is critical for the development of elastase-induced abdominal aortic aneurysm","volume":"119","author":"Pagano","year":"2009","journal-title":"Circulation"},{"key":"2025010608420221300_r71","doi-asserted-by":"crossref","first-page":"E415","DOI":"10.1073\/pnas.1119000109","article-title":"Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm","volume":"109","author":"Zhou","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025010608420221300_r72","first-page":"211","article-title":"Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae","volume":"92","author":"Ingwer","year":"1978","journal-title":"J. Lab. Clin. Med."},{"key":"2025010608420221300_r73","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1128\/CVI.00444-14","article-title":"Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic","volume":"21","author":"Shaughnessy","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"2025010608420221300_r74","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1128\/IAI.01280-08","article-title":"Phosphoethanolamine substitution of lipid A and resistance of Neisseria gonorrhoeae to cationic antimicrobial peptides and complement-mediated killing by normal human serum","volume":"77","author":"Lewis","year":"2009","journal-title":"Infect. Immun."},{"key":"2025010608420221300_r75","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J. Immunol."},{"key":"2025010608420221300_r76","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/IAI.02984-14","article-title":"Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity","volume":"83","author":"Giuntini","year":"2015","journal-title":"Infect. Immun."},{"key":"2025010608420221300_r77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/iai.55.1.174-180.1987","article-title":"Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation","volume":"55","author":"Jarvis","year":"1987","journal-title":"Infect. Immun."},{"key":"2025010608420221300_r78","doi-asserted-by":"crossref","first-page":"38476","DOI":"10.1074\/jbc.M307017200","article-title":"Formation of high affinity C5 convertase of the classical pathway of complement","volume":"278","author":"Rawal","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2025010608420221300_r79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/IAI.05956-11","article-title":"Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein","volume":"80","author":"Giuntini","year":"2012","journal-title":"Infect. Immun."},{"key":"2025010608420221300_r80","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.smim.2016.06.001","article-title":"New milestones ahead in complement-targeted therapy","volume":"28","author":"Ricklin","year":"2016","journal-title":"Semin. Immunol."}],"container-title":["ImmunoHorizons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/3\/11\/519\/60185373\/ih1900031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article-pdf\/3\/11\/519\/60185373\/ih1900031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:44:56Z","timestamp":1736153096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunohorizons\/article\/3\/11\/519\/7820566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.4049\/immunohorizons.1900031","relation":{},"ISSN":["2573-7732"],"issn-type":[{"value":"2573-7732","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,11,1]]}}}